Prognosis
Pfizer Begins Making Shot That Targets Omicron, Original Virus
- Drug giant also exploring higher doses, different regimens
- Modified shot could be submitted for U.S. clearance in March
This article is for subscribers only.
Pfizer Inc. is developing a hybrid vaccine that combines its original shot with a formulation that shields against the highly transmissible omicron variant, the drug giant’s top executive said.
While research continues, Pfizer will evaluate the new hybrid formulation against an omicron-specific shot, and determine which is best suited to move forward by March, Chief Executive Officer Albert Bourla said at the JPMorgan Healthcare Conference on Monday. Pfizer will be ready in March to approach U.S. regulators for clearance of the modified vaccine and bring it to market, and it has already begun production, Bourla said.